These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16914835)

  • 1. Relationship of cognitive measures and gray and white matter in Alzheimer's disease.
    Baxter LC; Sparks DL; Johnson SC; Lenoski B; Lopez JE; Connor DJ; Sabbagh MN
    J Alzheimers Dis; 2006 Aug; 9(3):253-60. PubMed ID: 16914835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease.
    Tai H; Hirano S; Sakurai T; Nakano Y; Ishikawa A; Kojima K; Li H; Shimada H; Kashiwado K; Mukai H; Horikoshi T; Sugiyama A; Uno T; Kuwabara S
    J Alzheimers Dis; 2020; 78(4):1639-1652. PubMed ID: 33185599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.
    Carmichael O; Schwarz C; Drucker D; Fletcher E; Harvey D; Beckett L; Jack CR; Weiner M; DeCarli C;
    Arch Neurol; 2010 Nov; 67(11):1370-8. PubMed ID: 21060014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
    Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
    Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.
    Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B
    Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting clinical scores from magnetic resonance scans in Alzheimer's disease.
    Stonnington CM; Chu C; Klöppel S; Jack CR; Ashburner J; Frackowiak RS;
    Neuroimage; 2010 Jul; 51(4):1405-13. PubMed ID: 20347044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
    Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C
    J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative.
    Song X; Mitnitski A; Zhang N; Chen W; Rockwood K;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):71-8. PubMed ID: 23123510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between cognitive impairment on ADAS-cog and regional cerebral blood flow using SPECT in late-onset Alzheimer's disease.
    Takahashi M; Oda Y; Okubo T; Shirayama Y
    J Neural Transm (Vienna); 2017 Sep; 124(9):1109-1121. PubMed ID: 28509077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional-structural degeneration in dorsal and ventral attention systems for Alzheimer's disease, amnestic mild cognitive impairment.
    Qian S; Zhang Z; Li B; Sun G
    Brain Imaging Behav; 2015 Dec; 9(4):790-800. PubMed ID: 25452158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study.
    Watson R; O'Brien JT; Barber R; Blamire AM
    Int Psychogeriatr; 2012 Apr; 24(4):532-40. PubMed ID: 22126938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
    Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
    J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion tensor imaging measures of normal appearing white matter in patients who are aging, or have amnestic mild cognitive impairment, or Alzheimer's disease.
    Wang JH; Lv PY; Wang HB; Li ZL; Li N; Sun ZY; Zhao BH; Huang Y
    J Clin Neurosci; 2013 Aug; 20(8):1089-94. PubMed ID: 23787190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial.
    Kamphuis PJ; Verhey FR; Olde Rikkert MG; Twisk JW; Swinkels SH; Scheltens P
    J Nutr Health Aging; 2011 Aug; 15(8):720-4. PubMed ID: 21968871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.